Research Topics
Species | J M RaeSummaryAffiliation: University of Michigan Country: USA Publications
| Collaborators
|
Detail Information
Publications
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cellsYoung Chai Lim
Division of Clinical Pharmacology, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
J Pharmacol Exp Ther 318:503-12. 2006..We conclude that endoxifen and 4-OH-Tam have similar effects on global gene expression patterns in MCF-7 cells and that the majority of the affected genes are estrogen-regulated genes...- CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
J Natl Cancer Inst 104:452-60. 2012..Previous studies have suggested that metabolic conversion of tamoxifen to endoxifen by cytochrome P450 2D6 (CYP2D6) is required for patient benefit from tamoxifen therapy... - When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?Chad J Creighton
Bioinformatics Program, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Breast Cancer Res 8:302. 2006..Recent gene expression profiling studies using cell line models to identify downstream transcriptional targets of oncogenic signaling pathways may help achieve this goal... - CYP2D6 genotype and tamoxifen responseJames M Rae
Breast Cancer Res 7:E6. 2005 - MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma researchJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, 1150 West Medical Center Drive, Med Sci I, Room 5323, Ann Arbor, MI 48109 0612, USA
Breast Cancer Res Treat 104:13-9. 2007..We could not determine, however, whether the melanoma-like properties of the MDA-MB-435 cell line are the result of misclassification or due to transdifferention to a melanoma-like phenotype... - The role of single nucleotide polymorphisms in breast cancer metastasisJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Breast Cancer Res 10:301. 2008..Although some provocative studies suggest potential candidates for metastasis regulating genes, the conclusive identification of a specific inherited genetic variant that alters metastatic potential awaits further studies... - GREB1 is a novel androgen-regulated gene required for prostate cancer growthJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
Prostate 66:886-94. 2006..GREB1 is expressed in the prostate and its putative promoter contains potential androgen receptor (AR) response elements... - What does an orphan G-protein-coupled receptor have to do with estrogen?James M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Breast Cancer Res 7:243-4. 2005..It has long been postulated that the rapid effects of estrogen are due to a membrane-bound ER, and two recent reports suggest that it is in fact a G-protein-coupled receptor named 'GPR30'... - GREB 1 is a critical regulator of hormone dependent breast cancer growthJames M Rae
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0612, USA
Breast Cancer Res Treat 92:141-9. 2005.... - Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae
Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0612, USA
Pharmacogenomics J 9:258-64. 2009..Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely... - Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsJames M Rae
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
Breast Cancer Res Treat 83:99-107. 2004..5 microM or less. However, higher doses (EC50's >or= 2 microM) were needed to block the growth of human tumor cell lines potentially implicating a second site of action for these compounds... - Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samplesJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, 5323 Med Sci 1, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
Pharmacogenetics 13:501-7. 2003..We set out to establish genotyping methods for relevant genes from archival tumor samples and determine if fixation, processing or somatic changes in the tumor might affect our ability to identify germ-line polymorphisms... - Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolismJames M Rae
Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
Drug Metab Dispos 30:525-30. 2002..Furthermore, thioTEPA may prove to be a valuable new tool for the study of this important drug-metabolizing enzyme... - EGFR and EGFRvIII expression in primary breast cancer and cell linesJames M Rae
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0612, USA
Breast Cancer Res Treat 87:87-95. 2004..In contrast, EGFRwt was expressed at varying levels in the majority of samples tested. We conclude that the expression of EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phenotype... - Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated resultsD F Hayes
Department of Internal Medicine and Breast Oncology Program, Comprehensive Cancer Center, University of Michigan Health and Hospitals System, Ann Arbor, Michigan, USA
Clin Pharmacol Ther 88:626-9. 2010.... - Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapyN L Henry
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
Br J Cancer 102:294-300. 2010..We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone... - Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibodyH J Hnatyszyn
Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA
Breast Cancer Res Treat 122:371-80. 2010..The novel monoclonal GREB1ab is specific for GREB1 protein. This antibody will serve as a tool for investigations focused on the expression, distribution, and function of GREB1 in normal breast and breast cancer tissues... - Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growthM J Sikora
Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI, USA
HIV Med 11:603-7. 2010..Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER)... - CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentYan Jin
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Natl Cancer Inst 97:30-9. 2005.... - Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Clin Oncol 23:9312-8. 2005..Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown... - Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineVered Stearns
The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J Natl Cancer Inst 95:1758-64. 2003..Coadministration of paroxetine decreased the plasma concentration of endoxifen. Our data suggest that CYP2D6 genotype and drug interactions should be considered in women treated with tamoxifen... - Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma propertiesJames M Rae
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Clin Exp Metastasis 21:543-52. 2004..Collectively, our results show that the MDA-MB-435 cells used widely have identical origins to those that exhibit a melanoma-like gene expression signature, but exhibit a small degree of genotypic and phenotypic drift... - High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissuesM J Sikora
Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Pharmacogenomics J 11:348-58. 2011..The use of tumor cores is of particular importance as the harvesting of tumor cores has minimal impact on the utility of the donor blocks for other purposes... - The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistanceMatthew J Sikora
Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Breast Cancer Res Treat 115:289-96. 2009..The generation of estrogen-like steroids represents a potential mechanism of resistance to aromatase inhibitors... - An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor statusMarc E Lippman
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Trans Am Clin Climatol Assoc 119:77-90; discussion 90-2. 2008..This combined biological and informatic analysis is potentially applicable to many other cancer therapeutics... - Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumorsChad J Creighton
Bioinformatics Program, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Genome Biol 7:R28. 2006..CONCLUSION: Our results provide significant validation of a widely used in vitro model of estrogen signaling as being pathologically relevant to breast cancers in vivo... - The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
Breast Cancer Res Treat 101:113-21. 2007.... - Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessmentMichelle A Anderson
Department of Internal Medicine, Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109 0362, USA
J Mol Diagn 12:566-75. 2010..Fine needle aspirates (FNAs) from pancreatic masses were studied to define potential causes of RNA degradation and develop methods for accurately measuring gene expression... - Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanismsErin Harleton
Department of Pharmacology, Medical Science Research Building III, 1150 West Medical Center Dr, Ann Arbor, MI 48109 0632, USA
J Pharmacol Exp Ther 310:1011-9. 2004..The data indicate that tTEPA metabolism by these two 2B isoforms results in inactivation of the P450s by two distinct mechanisms... - Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
Breast Cancer Res Treat 117:571-5. 2009..062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy... - Monitoring serial changes in circulating human breast cancer cells in murine xenograft modelsJean Pierre Eliane
Breast Oncology Program, Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0942, USA
Cancer Res 68:5529-32. 2008..These results establish a new method for studying CTC in mouse models of epithelial cancer, providing the foundation for studies of molecular regulation of CTC in cancer and CTC as biomarker for therapeutic efficacy... - Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing schemeAnne F Schott
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
Cancer Chemother Pharmacol 58:129-35. 2006..A flat dosing scheme of both drugs was used to facilitate development of the oral regimen, and because neither drug's clearance is associated with body surface area (BSA), pharmacokinetic and pharmacogenetic endpoints were explored... - Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell linesEdith J Mensah-Osman
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Cancer 109:957-65. 2007.... - Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arraysJ M Rae
Department of Pharmacology, Georgetown University Medical Center, Washington, DC, USA
J Pharmacol Exp Ther 299:849-57. 2001..Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects... - Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumorsChad J Creighton
Bioinformatics Program, University of Michigan Medical Center, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA
Cancer Res 66:3903-11. 2006..These MAPK+ cell lines are excellent models for investigating the underlying mechanisms behind the ERalpha- phenotype... - Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistanceMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 14:5864-8. 2008..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer... - Cytochrome P450 3A pharmacogenetics: the road that needs traveledD A Flockhart
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis 46202, USA
Pharmacogenomics J 3:3-5. 2003 - (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancerLiang Xu
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, 5301B Medical Science Research Building III, 1500 West Medical Center Drive, Ann Arbor, MI 48109-0640, USA
Mol Cancer Ther 4:197-205. 2005..Gossypol may improve the outcome of current prostate cancer radiotherapy and represents a promising novel anticancer regime for molecular targeted therapy of hormone-refractory prostate cancer with Bcl-2/Bcl-xL overexpression... - The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6Natasha T Snider
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109 5632, USA
J Pharmacol Exp Ther 327:538-45. 2008..This study also offers support to the hypothesis that neuropsychiatric phenotype differences among individuals with genetic variations in CYP2D6 could be ascribable to interactions of this enzyme with endogenous substrates... - LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell linesErik W Thompson
Invasion and Metastasis Unit, University of Melbourne, Department of Surgery, St Vincent s Hospital, 29 Regent St, Fitzroy, 3065, Australia
Clin Exp Metastasis 21:535-41. 2004..We also review the known misclassification of breast and prostate cancer cell lines to date and have initiated a register maintained at http://www.svi.edu.au/cell_lines_registry.doc... - A transcriptional fingerprint of estrogen in human breast cancer predicts patient survivalJianjun Yu
Bioinformatigram, The University of of Michigan Medical Center, Ann Arbor, MI 48109 USA
Neoplasia 10:79-88. 2008..Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance... - Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19Million Arefayene
Department of Medicine Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Pharmacogenetics 13:199-206. 2003..These data make possible future studies to elucidate the molecular mechanisms by which CYP2C19 can be induced in clinical settings and the consequences of genetic variability in its promoter... - Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsSusan A Nowell
Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Breast Cancer Res Treat 91:249-58. 2005..These studies indicate that genetic variation in Phase II conjugating enzymes can influence the efficacy of tamoxifen therapy for breast cancer...